AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 and 0.2 mg)
Number of subjects: 6
Study 8138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (45 and 60 mg)
Number of subjects: 6
Study 8138958 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 3202400 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 9
Study 3202400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31846499 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT on agonist muscles (B)
Number of subjects: 82
Study 31846499 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT on antagonist muscles (C)
Number of subjects: 82
Study 31846499 — intervention group
Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 82
Study 29167951 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization (RE)
Number of subjects: 11
Study 29167951 — intervention group
Group type: COMPARATOR
Intervention: Bland hepatic arterial embolization (HAE)
Number of subjects: 11
Study 28247424 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Drinking Screen (QDS)
Number of subjects: 472
Study 28247424 — intervention group
Group type: COMPARATOR
Intervention: AUDIT-C
Number of subjects: 472
Study 26413145 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth exercises plus standard of care
Number of subjects: 50
Study 26413145 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 50
Study 23146410 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 324
Study 23146410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 20806703 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate preparation with resin AH26 sealer
Number of subjects: 86
Study 20806703 — intervention group
Group type: COMPARATOR
Intervention: Delayed preparation with resin AH26 sealer
Number of subjects: 86
Study 20806703 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate preparation with ZOE Dorifil sealer
Number of subjects: 86
Study 20806703 — intervention group
Group type: COMPARATOR
Intervention: Delayed preparation with ZOE Dorifil sealer
Number of subjects: 86
Study 18338313 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-imputation strategy for correlated ordinal responses
Number of subjects: 0
Study 16168729 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend color group
Number of subjects: 2
Study 16168729 — intervention group
Group type: COMPARATOR
Intervention: Ignore group
Number of subjects: 2
Study 12750624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 5% (Exacyl) mouthwashes prescribed during and after surgery
Number of subjects: 40
Study 10096932 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing at LV free-wall
Number of subjects: 18
Study 10096932 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 18
Study 10096932 — intervention group
Group type: COMPARATOR
Intervention: RV pacing
Number of subjects: 18
Study 10096932 — intervention group
Group type: EXPERIMENTAL
Intervention: LV pacing
Number of subjects: 18
Study 8671343 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 54
Study 8671343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (35 micrograms ethinyl oestradiol and 1 mg norethindrone)
Number of subjects: 54
Study 8671343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (50 micrograms ethinyl oestradiol and 1 mg norethindrone)
Number of subjects: 54
Study 8671343 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 800 mg/day
Number of subjects: 54
Study 1751239 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hour (SH) dialysis using AN69S plus volumetric control (VC)
Number of subjects: 112
Study 1751239 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CNV) cellulosic non-VC dialysis
Number of subjects: 112
Study 1751239 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hour (SH) dialysis
Number of subjects: 112
Study 378729 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol (160 mg/day)
Number of subjects: 18
Study 378729 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg three times daily)
Number of subjects: 18
Study 31590967 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) therapy
Number of subjects: 2368
Study 31590967 — intervention group
Group type: COMPARATOR
Intervention: Insulin-providing (IP) therapy
Number of subjects: 2368
Study 31590967 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (REV)
Number of subjects: 2368
Study 31590967 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (MED)
Number of subjects: 2368
Study 31590967 — intervention group
Group type: EXPERIMENTAL
Intervention: IS therapy with REV
Number of subjects: 2368
Study 31590967 — intervention group
Group type: COMPARATOR
Intervention: IP therapy with REV
Number of subjects: 2368
Study 31590967 — intervention group
Group type: EXPERIMENTAL
Intervention: IS therapy with MED
Number of subjects: 2368
Study 31590967 — intervention group
Group type: COMPARATOR
Intervention: IP therapy with MED
Number of subjects: 2368
Study 31590967 — intervention group
Group type: EXPERIMENTAL
Intervention: IS therapy and REV in CABG preselected patients
Number of subjects: 2368
Study 28195501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) stress management programme
Number of subjects: 362
Study 28195501 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 362
Study 26313794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward nurse education
Number of subjects: 205
Study 26313794 — intervention group
Group type: COMPARATOR
Intervention: Control ward (no nurse education)
Number of subjects: 205
Study 23552787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composites
Number of subjects: 104
Study 23552787 — intervention group
Group type: COMPARATOR
Intervention: Wire-ligation fixation
Number of subjects: 104
Study 22310866 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized peristomal skin care (SPSC)
Number of subjects: 81
Study 22310866 — intervention group
Group type: COMPARATOR
Intervention: Crusting technique (CT)
Number of subjects: 81
Study 22310866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SPSC and CT
Number of subjects: 81
Study 19583650 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction using kaleidoscopes
Number of subjects: 206
Study 19583650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 206
Study 17407645 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib/atorvastatin (T/A) - torcetrapib dose 60 mg, atorvastatin dose 20-80 mg (RADIANCE 1) or 10-80 mg (RADIANCE 2)
Number of subjects: 1656
Study 17407645 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone - atorvastatin dose 20-80 mg (RADIANCE 1) or 10-80 mg (RADIANCE 2)
Number of subjects: 1656
Study 15126715 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g x d of mixed CLA isomers for 8 wk
Number of subjects: 16
Study 15126715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 16
Study 11228472 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 24
Study 11228472 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 24
Study 9512220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin‐releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG)
Number of subjects: 564
Study 9512220 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG) only
Number of subjects: 564
Study 9512220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administration
Number of subjects: 564
Study 9512220 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 564
Study 8069190 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (n = 147)
Number of subjects: 287
Study 8069190 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus methotrexate (n = 46)
Number of subjects: 287
Study 8069190 — intervention group
Group type: COMPARATOR
Intervention: CHOP (n = 44)
Number of subjects: 287
Study 8069190 — intervention group
Group type: COMPARATOR
Intervention: Intermittent chlorambucil plus prednisone (n = 140)
Number of subjects: 287
Study 2460352 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 75 MBq 89Sr
Number of subjects: 49
Study 30861426 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 100
Study 30861426 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate cauterization
Number of subjects: 100
Study 27605543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist review of all medication according to the Good Palliative‐Geriatric Practice algorithm and the Screening Tool of Older Person's Prescriptions‐Screening Tool to Alert Doctors to the Right Treatment
Number of subjects: 503
Study 27605543 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice
Number of subjects: 503
Study 25162916 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion prepared from 2, 4, or 8 g of C. citratus leaves once daily for 30 days
Number of subjects: 105
Study 22168624 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate
Number of subjects: 30
Study 22168624 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone chips
Number of subjects: 30
Study 22168624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 21904641 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation at 1,200 mg daily for 7 days
Number of subjects: 29
Study 21904641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC supplementation)
Number of subjects: 29
Study 21904641 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation
Number of subjects: 29
Study 18089630 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 898
Study 18089630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 898
Study 17942871 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 10154
Study 17942871 — intervention group
Group type: COMPARATOR
Intervention: Pap testing
Number of subjects: 10154
Study 17942871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests used together
Number of subjects: 10154
Study 17942871 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage procedures for Pap or HPV testing
Number of subjects: 10154
Study 14506092 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma
Number of subjects: 13
Study 14506092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13
Study 11167642 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physiotherapy
Number of subjects: 530
Study 11167642 — intervention group
Group type: COMPARATOR
Intervention: Group physiotherapy
Number of subjects: 530
Study 9603667 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantan lotion containing 0.1% methylprednisolone aceponate applied on intact skin
Number of subjects: 6
Study 9603667 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantan lotion containing 0.1% methylprednisolone aceponate applied on inflamed skin
Number of subjects: 6
Study 9603667 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantan lotion containing 0.1% methylprednisolone aceponate applied on stripped skin
Number of subjects: 6
Study 7921293 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based health maintenance tracking system
Number of subjects: 0
Study 7921293 — intervention group
Group type: COMPARATOR
Intervention: Manual flowchart-based tracking system
Number of subjects: 0
Study 2965374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A: 8 mg/kg/day at 07.00 h and 4 mg/kg/day at 19.00 h
Number of subjects: 12
Study 2965374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B: 6 mg/kg/day at 07.00 h and 6 mg/kg/day at 19.00 h
Number of subjects: 12
Study 2965374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C: 4 mg/kg/day at 07.00 h and 8 mg/kg/day at 19.00 h
Number of subjects: 12
Study 31059974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (Faslodex)
Number of subjects: 0
Study 31059974 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study 27856267 — intervention group
Group type: EXPERIMENTAL
Intervention: Stemless shoulder prosthesis (group 1)
Number of subjects: 40
Study 27856267 — intervention group
Group type: COMPARATOR
Intervention: Standard stem humeral head replacement (group 2)
Number of subjects: 40
Study 27856267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 28537365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish group
Number of subjects: 758
Study 28537365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 758
Study 24642580 — intervention group
Group type: COMPARATOR
Intervention: Standard Triple Therapy (STT) - 10 days of treatment with esomeprazole, amoxicillin, and clarithromycin
Number of subjects: 280
Study 24642580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) - 5 days of esomeprazole and amoxicillin, followed by 5 days of esomeprazole, clarithromycin, and tinidazole
Number of subjects: 280
Study 24642580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) with dual CLA-R and MET-R
Number of subjects: 280
Study 24642580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) with isolated CLA-R
Number of subjects: 280
Study 24642580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) with isolated MET-R
Number of subjects: 280
Study 21748722 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid (375 mg daily, titrated to 500, 750, and 1,000 mg as tolerated)
Number of subjects: 28
Study 21748722 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid
Number of subjects: 28
Study 21748722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19527380 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron folic acid (Group I, n = 30)
Number of subjects: 90
Study 19527380 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron folic acid (Group II, n = 30)
Number of subjects: 90
Study 19527380 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron (III)-hydroxide polymaltose complex (Group III, n = 30)
Number of subjects: 90
Study 17966618 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 blocker (famotidine 20 mg)
Number of subjects: 87
Study 17966618 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 87
Study 16238560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg(‐1) loading dose, 0.2 mg.kg(‐1) bolus doses)
Number of subjects: 60
Study 16238560 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg.kg(‐1) loading dose, 0.02 mg.kg(‐1) bolus doses)
Number of subjects: 60
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy alone
Number of subjects: 87
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring alone
Number of subjects: 87
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both combined
Number of subjects: 87
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 87
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment sense of control/internal attribution
Number of subjects: 87
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline beliefs
Number of subjects: 87
Study 11883725 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in beliefs
Number of subjects: 87
Study 9579626 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium reinforced barrier membranes
Number of subjects: 15
Study 9579626 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue grafts
Number of subjects: 15
Study 8131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 9
Study 8131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 9
Study 8131679 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-kcal meal
Number of subjects: 9
Study 8131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise distension
Number of subjects: 9
Study 8131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent distension
Number of subjects: 9
Study 8131679 — intervention group
Group type: COMPARATOR
Intervention: Stepwise distension (IBS vs Controls)
Number of subjects: 9
Study 8131679 — intervention group
Group type: COMPARATOR
Intervention: Intermittent distension (IBS vs Controls)
Number of subjects: 9
Study 2573286 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 252
Study 2573286 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 252
Study 31852424 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 55
Study 31852424 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study 31233135 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation (TR) system, 36 sessions of arm motor therapy plus stroke education, 70 minutes each session.
Number of subjects: 124
Study 31233135 — intervention group
Group type: COMPARATOR
Intervention: In-clinic therapy (IC), 36 sessions of arm motor therapy plus stroke education, 70 minutes each session.
Number of subjects: 124
Study 28043880 — intervention group
Group type: EXPERIMENTAL
Intervention: QLF technology combined with visual inspection
Number of subjects: 92
Study 28043880 — intervention group
Group type: COMPARATOR
Intervention: Conventional visual inspection alone (Control)
Number of subjects: 92
Study 28043880 — intervention group
Group type: EXPERIMENTAL
Intervention: QLF technology
Number of subjects: 92
Study 25730649 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV + RE
Number of subjects: 10
Study 25730649 — intervention group
Group type: COMPARATOR
Intervention: RE only
Number of subjects: 10
Study 23558158 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 353
Study 23558158 — intervention group
Group type: COMPARATOR
Intervention: Health Education (Control)
Number of subjects: 353
Study 21418153 — intervention group
Group type: EXPERIMENTAL
Intervention: Opened mouth - sniffing position (OS)
Number of subjects: 40
Study 18359872 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for nephropathy followed by treatment with irbesartan 300 mg
Number of subjects: 0
Study 18359872 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 16573708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-vas device (IVD)
Number of subjects: 288
Study 16573708 — intervention group
Group type: COMPARATOR
Intervention: No-scalpel vasectomy (NSV)
Number of subjects: 288
Study 12705572 — intervention group
Group type: EXPERIMENTAL
Intervention: Referential condition (novel words or novel nonverbal sounds with social-referential interaction)
Number of subjects: 2
Study 12705572 — intervention group
Group type: COMPARATOR
Intervention: Nonreferential condition (novel words or novel nonverbal sounds emitted from a baby monitor)
Number of subjects: 2
Study 10735784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 41
Study 10735784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9014265 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom suicide response lessons
Number of subjects: 0
Study 9014265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 9014265 — intervention group
Group type: EXPERIMENTAL
Intervention: All students (both intervention and control)
Number of subjects: 0
Study 1407927 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral acupressure
Number of subjects: 60
Study 1407927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral acupressure
Number of subjects: 60
Study 1407927 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 60
Study 3906162 — intervention group
Group type: EXPERIMENTAL
Intervention: Travasorb‐Hepatic (BCAA rich supplement)
Number of subjects: 8
Study 3906162 — intervention group
Group type: COMPARATOR
Intervention: Ensure (casein based supplement)
Number of subjects: 8
Study 29573335 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept more intense (MI)
Number of subjects: 100
Study 29573335 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept less intense (LI)
Number of subjects: 100
Study 29573335 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 100
Study 26879752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic cystolithotripsy (CL)
Number of subjects: 25
Study 26879752 — intervention group
Group type: COMPARATOR
Intervention: Holmium: YAG laser cystolithotripsy (Ho:YAG CL)
Number of subjects: 25
Study 24223416 — intervention group
Group type: EXPERIMENTAL
Intervention: Well adapted (WA)
Number of subjects: 24
Study 24223416 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately well adapted (MA)
Number of subjects: 24
Study 24223416 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly adapted (PA)
Number of subjects: 24
Study 22455412 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 70 mg
Number of subjects: 198
Study 22455412 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 198
Study 22455412 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 198
Study 22455412 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 198
Study 22455412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 20737516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (add-on treatment)
Number of subjects: 39